Texas Capital (TCBI) - FREE Research Report

Hegi Frederick B Jr who is Director at Texas Capital sold 10,000 shares at $62.68 on March 7, 2014. Following this transaction, the Director owned 33,000 shares meaning that the stake was reduced by 23.26% with the 10,000-share transaction.

The shares most recently traded at $64.86, up $2.18, or 3.36% since the insider transaction. Historical insider transactions for Texas Capital go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 27,075
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 27,075
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 27,075

The average volume for Texas Capital has been 536,800 shares per day over the past 30 days. Texas Capital has a market cap of $2.7 billion and is part of the financial sector and banking industry. Shares are up 2.88% year-to-date as of the close of trading on Friday.

Texas Capital Bancshares, Inc. operates as the bank holding company for Texas Capital Bank, National Association that provides various banking products and services for commercial businesses, and professionals and entrepreneurs in Texas. The company has a P/E ratio of 23.5. Currently there are 6 analysts that rate Texas Capital a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TCBI - FREE

TheStreet Quant Ratings rates Texas Capital as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Texas Capital Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Insider Trading Alert - LPNT, PATK And CTIC Traded By Insiders

Insider Trading Alert - SPTN, FL And CTIC Traded By Insiders